Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine

Fig. 1

Expression level of miR-29c and impact of miR-29c expression on OS in AML patients. a The level of miR-29c expression in controls and AML patients by RQ-PCR. b Discriminative capacity of miR-29c expression by ROC curve analysis for miR-29c AML patients. c Discriminative capacity of miR-29c expression by ROC curve analysis for CN-AML patients. d Prognostic value of miR-29c expression in whole AML patients. e Prognostic value of miR-29c expression in CN-AML patients. Overall survival (OS) was analyzed between miR-29c high and miR-29c low groups

Back to article page